Senator Josh Hawley has introduced a new bill aiming to revoke FDA approval for mifepristone, a widely used medication for abortion. This legislation builds on previous efforts to restrict access, framing the drug as inherently dangerous and potentially abusive.
The proposed “Safeguarding Women from Chemical Abortion Act” would effectively prohibit the use of mifepristone to end pregnancies. Senator Hawley argues that companies profiting from the drug are prioritizing financial gain over women’s health, citing concerns about potential complications.
If enacted, the bill would not only withdraw FDA approval but also classify the distribution of mifepristone for abortion as a federal offense. This move comes as mifepristone is used in a significant majority – 63% – of all abortions performed in the United States.
Data suggests over one million abortions were performed in 2024, though this figure is limited to states without restrictive abortion laws and doesn’t account for all methods or locations. The debate surrounding mifepristone is therefore occurring within a complex and evolving landscape of reproductive healthcare access.
Senator Hawley previously proposed legislation focused on increasing safeguards around mifepristone, granting women the right to sue telehealth providers and pharmacies in cases of complications. This latest bill represents a more forceful attempt to curtail access to the medication.
Recent research from the Ethics and Public Policy Center indicates that reported side effects from mifepristone are considerably higher than what the FDA’s approved label suggests. The study, analyzing insurance claims, found over 10% of women experienced infection, hemorrhaging, or other serious adverse events.
The FDA has recently expanded access to mifepristone, allowing prescriptions via telehealth, eliminating the requirement for in-person doctor visits. This change has been a focal point of legal challenges and political debate.
The Supreme Court recently dismissed a challenge seeking to overturn the FDA’s approval and expanded access to mifepristone, but the ruling was based on legal standing, not on the drug’s safety or efficacy. The court did not address the core arguments against the medication.
Senator Hawley has directly appealed to the FDA Commissioner, urging a review of new data and reinstatement of stricter safeguards. He referenced a previous pledge from the commissioner to consider all available information regarding the drug’s safety profile.
The core of the argument centers on the health and safety of women, with proponents of the bill asserting that current regulations are insufficient to protect patients. This debate highlights the deeply divisive nature of abortion access and the ongoing scrutiny of medications used in the process.
